Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has scheduled a business update conference call and webcast for March 24, 2025, at 8:30 AM ET.

During the call, Chairman and CEO Lishan Aklog will provide a comprehensive business update, including the company's operations and growth strategy. CFO Dennis McGrath will present the fourth quarter 2024 financial results.

Investors can access the webcast through the company's investor relations website at luciddx.com. For telephone access:

• U.S. callers: 1-800-836-8184
• International callers: 1-646-357-8785

Participants should reference "Lucid Diagnostics Business Update" when joining. A 30-day replay will be available on the company's investor relations website following the call.

Conference Call and Webcast at 8:30 AM Eastern Time

NEW YORK, March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2024 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-march-24-2025-302396541.html

SOURCE Lucid Diagnostics

FAQ

When is Lucid Diagnostics (LUCD) Q4 2024 earnings call scheduled?

Lucid Diagnostics' Q4 2024 earnings call is scheduled for March 24, 2025, at 8:30 AM Eastern Time.

How can investors access LUCD's March 24 business update call?

Investors can join via webcast at luciddx.com, or by phone: U.S. callers (1-800-836-8184) or international callers (1-646-357-8785).

What topics will be covered in Lucid Diagnostics' March 2025 business update?

The call will cover company operations, growth strategy, and Q4 2024 financial results.

How long will the replay of LUCD's March 24 earnings call be available?

The conference call replay will be available for 30 days on Lucid Diagnostics' investor relations website.

Which executives will present at Lucid Diagnostics' Q4 2024 earnings call?

CEO Lishan Aklog will provide the business update, and CFO Dennis McGrath will present financial results.